Having trouble accessing articles? Reset your cache.

Tanezumab: Additional Phase II data

The double-blind, U.S. Phase II RN624-CL006 trial in 450 patients with moderate-to-severe knee pain due to OA of the knee showed that 10, 25, 50, 100 and

Read the full 276 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE